M&A Deal Summary

Novo Nordisk Acquires Dicerna

On November 18, 2021, Novo Nordisk acquired life science company Dicerna for 3.3B USD

Acquisition Highlights
  • This is Novo Nordisk’s 5th transaction in the Life Science sector.
  • This is Novo Nordisk’s largest (disclosed) transaction.
  • This is Novo Nordisk’s 4th transaction in the United States.
  • This is Novo Nordisk’s 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2021-11-18
Target Dicerna
Sector Life Science
Buyer(s) Novo Nordisk
Deal Type Add-on Acquisition
Deal Value 3.3B USD

Target

Dicerna

Lexington, Massachusetts, United States
Dicerna is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using proprietary RNAi technologies, GalXC and GalXC-Plus, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. Dicerna was founded in 2006 and is based in Lexington, Massachusetts.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Novo Nordisk

Bagsvaerd, Denmark
Category Company
Founded 1923
Sector Life Science
Employees48,000
Revenue 232.3B DKK (2023)
DESCRIPTION
Novo Nordisk office in Zurich, Switzerland.
Novo Nordisk office in Zurich, Switzerland.

Novo Nordisk is a global pharmaceutical company dedicated to improving the lives of individuals affected by diabetes and other serious chronic conditions. Novo Nordisk develops and provides a comprehensive range of treatments, therapies, and medical solutions that help patients manage their health effectively. Novo Nordisk was formed in 1923 and is based in Bagsvaerd, Denmark.

DEAL STATS #
Overall 5 of 8
Sector (Life Science) 5 of 8
Type (Add-on Acquisition) 5 of 8
State (Massachusetts) 2 of 3
Country (United States) 4 of 5
Year (2021) 1 of 1
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-11 Corvidia Therapeutics

Waltham, Massachusetts, United States

Corvidia Therapeutics, Inc. is a clinical-stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis. Corvidia Therapeutics was founded in 2015 and is headquartered in Waltham, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-09-01 Forma Therapeutics

Watertown, Massachusetts, United States

Forma Therapeutics is a fully-integrated, privately-held clinical-stage biopharmaceutical company. A leader in metabolism, epigenetics, and protein homeostasis focused on the discovery, development, and commercialization of transformative medicines. It's proprietary R&D platform combines deep biology insight, chemistry expertise, and clinical development capabilities to create differentiated drug candidates. The company has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications. Forma Therapeutics was formed in 2007 and is based in Watertown, Massachusetts.

Buy $1.1B
Mergr

Product

Company

Legal